|
|
|
|
| LEADER |
01431nam a2200337 u 4500 |
| 001 |
EB001888790 |
| 003 |
EBX01000000000000001052151 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200106 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Ertugliflozin (Steglatro -- Merck Canada Inc.)
|h Elektronische Ressource
|b indication : diabetes mellitus, type 2
|
| 246 |
3 |
1 |
|a Ertugliflozin (Steglatro -- Merck Canada Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Ertugliflozin (Steglatro)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2019, January 25, 2019
|
| 300 |
|
|
|a 1 PDF file (7 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
|
| 653 |
|
|
|a Bridged Bicyclo Compounds, Heterocyclic / economics
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors / economics
|
| 653 |
|
|
|a Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK542402
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|